CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
PHOENIX, Aug. 8, 2025 /PRNewswire/ -- PetSmart LLC ("PetSmart") announced today that, together with its wholly-owned subsidiary, PetSmart Finance Corp. (the "Co-Issuer" and, together...
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Bidding War Expected for Legendary Firearm as Eyes Turn to Caracas
BEDFORD, Texas, Aug. 8, 2025 /PRNewswire/ -- An ornate presentation flintlock owned by South...
Company received $300 million in connection with the Exchange Offer on August 8, 2025
Holders of approximately 98% of the aggregate principal amount of the...
ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and six-month periods ended June 28, 2025.
Revises full year 2025 Net Sales, Adjusted EBITDA, and Adjusted Free Cash Flow guidanceReaffirms cost synergy capture targets of $200 million in 2025; $300...
WAYNE, Pa., Aug. 7, 2025 /PRNewswire/ -- Ecovyst Inc. (NYSE: ECVT) ("Ecovyst" or the "Company"), a leading integrated and innovative global provider of advanced...
LOS ANGELES, Aug. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit...
MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.